Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis
An Open-Label Study Evaluating Enstilar® (Calcipotriene and Betamethasone Dipropionate) Foam, 0.005%/0.064% QD in Psoriasis Patients Being Treated With Etanercept or Adalimumab
Psoriasis Treatment Center of Central New Jersey
30 participants
Jan 16, 2019
INTERVENTIONAL
Conditions
Summary
4 weeks of adjunctive therapy of Enstilar® QD followed by 12 weeks QOD to patients with 2-10% BSA who are receiving etanercept or adalimumab for at least 24 weeks
Eligibility
Inclusion Criteria5
- Male or female adult ≥ 18 years of age;
- Diagnosis of chronic plaque-type
- Patient with 2-10% BSA
- Physician Global Assessment of 2 or greater
- Patient has been treated with etanercept or adalimumab for a minimum of 24 weeks
Exclusion Criteria3
- ˂2 or \>10% BSA
- PGA \<2
- Patient not receiving etanercept or adalimumab, or receiving etanercept or adalimumab \<24weeks
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Enstilar 0.005%-0.064% Topical Foam applied once daily for 4 weeks followed by QOD for 12 weeks for patients receiving Enbrel or Humira
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03827876